|
- Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines
TORONTO, Jan. 21, 2026 /PRNewswire/ -- Daiichi Sankyo (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology.
"Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada's role as a global contributor to improve standards of care."
"Our government is protecting Ontario by cutting taxes and red tape, saving businesses $12 billion a year so that we can drive economic growth and welcome investments just like this one. Daiichi Sankyo's investment will help create good-paying jobs, strengthen our economy and reinforce Ontario's position as a world-class hub for innovation and health research. I want to thank Daiichi Sankyo for their confidence in Ontario's incredible workers," said Ontario Premier Doug Ford.
"This opening marks the beginning of an exciting new chapter for Daiichi Sankyo in Canada where we are further establishing our presence in Toronto as we continue to expand access to our oncology portfolio," added Fatih Yedikardeş, Country Manager, Canada, Daiichi Sankyo. "This expansion means improving access to our medicines and strengthening our partnerships with healthcare professionals and the broader life sciences community in Canada."
"As the largest life sciences jurisdiction in Canada, Ontario is a prime location for domestic and international pharmaceutical companies to establish their headquarters and advance their research from lab to market. We congratulate Daiichi Sankyo on the opening of their new Canadian headquarters here in Toronto and look forward to seeing the next chapter of their biomedical innovation that will leverage Ontario's highly skilled workforce and R&D capabilities," said Vic Fedeli, Ontario Minister of Economic Development, Job Creation and Trade.
Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with top cancer centres such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital.
"By establishing their Canadian headquarters in Toronto, Daiichi Sankyo is affirming Ontario's place as a hub of health innovation. This investment in Ontario will advance access to innovative cancer medicines for Ontario families, building on our government's actions to date to connect patients to cutting-edge, life-saving cancer drugs faster," added Sylvia Jones, Ontario Deputy Premier and Minister of Health.
To mark the occasion, Daiichi Sankyo hosted an office opening celebration featuring a traditional Kagami Biraki (sake barrel breaking) ceremony, symbolizing new beginnings, harmony and prosperity, followed by a Japanese taiko drumming performance honouring the company's cultural heritage. The event brought together company leadership, government representatives and partners to commemorate the milestone.
The official opening of the Daiichi Sankyo headquarters in Canada cements its position as a dedicated partner in the Canadian healthcare system. Driven by strategic investment and a rapidly expanding team, Daiichi Sankyo is focused on accelerating access to its oncology pipeline and building a healthier future for Canadians.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.
Media Contact: Sarah Douglas, Media_ca@daiichisankyo.com
- Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines
TORONTO, Jan. 21, 2026 /PRNewswire/ -- Daiichi Sankyo (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology.
"Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada's role as a global contributor to improve standards of care."
"Our government is protecting Ontario by cutting taxes and red tape, saving businesses $12 billion a year so that we can drive economic growth and welcome investments just like this one. Daiichi Sankyo's investment will help create good-paying jobs, strengthen our economy and reinforce Ontario's position as a world-class hub for innovation and health research. I want to thank Daiichi Sankyo for their confidence in Ontario's incredible workers," said Ontario Premier Doug Ford.
"This opening marks the beginning of an exciting new chapter for Daiichi Sankyo in Canada where we are further establishing our presence in Toronto as we continue to expand access to our oncology portfolio," added Fatih Yedikardeş, Country Manager, Canada, Daiichi Sankyo. "This expansion means improving access to our medicines and strengthening our partnerships with healthcare professionals and the broader life sciences community in Canada."
"As the largest life sciences jurisdiction in Canada, Ontario is a prime location for domestic and international pharmaceutical companies to establish their headquarters and advance their research from lab to market. We congratulate Daiichi Sankyo on the opening of their new Canadian headquarters here in Toronto and look forward to seeing the next chapter of their biomedical innovation that will leverage Ontario's highly skilled workforce and R&D capabilities," said Vic Fedeli, Ontario Minister of Economic Development, Job Creation and Trade.
Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with top cancer centres such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital.
"By establishing their Canadian headquarters in Toronto, Daiichi Sankyo is affirming Ontario's place as a hub of health innovation. This investment in Ontario will advance access to innovative cancer medicines for Ontario families, building on our government's actions to date to connect patients to cutting-edge, life-saving cancer drugs faster," added Sylvia Jones, Ontario Deputy Premier and Minister of Health.
To mark the occasion, Daiichi Sankyo hosted an office opening celebration featuring a traditional Kagami Biraki (sake barrel breaking) ceremony, symbolizing new beginnings, harmony and prosperity, followed by a Japanese taiko drumming performance honouring the company's cultural heritage. The event brought together company leadership, government representatives and partners to commemorate the milestone.
The official opening of the Daiichi Sankyo headquarters in Canada cements its position as a dedicated partner in the Canadian healthcare system. Driven by strategic investment and a rapidly expanding team, Daiichi Sankyo is focused on accelerating access to its oncology pipeline and building a healthier future for Canadians.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.
Media Contact: Sarah Douglas, Media_ca@daiichisankyo.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Newborn Town Inc. (Newborn Town or the company, stock code: 09911.HK), a leading global social entertainment company, released its unaudited operating data for 2025.
For the year ended 31 December 2025, the company's total revenue is estimated to reach approximately RMB 6,760 million to RMB 7,000 million, reflecting a year-on-year increase of approximately 32.8 % to 37.5 %.
Among the total revenue, social networking business contributed approximately RMB 6,030 million to RMB 6,230 million, up approximately 30.4% to 34.8% year-on-year. The innovative business saw a year-on-year growth of about 55.7% to 64.2% to approximately RMB 730 million to RMB 770 million, continuing its robust growth momentum.
In 2025, the company further deepened the integration of AI technologies into its business operations, enhancing user experience and product commercialization efficiency across business segments and driving high-quality growth.
Social Networking Business Maintains Strong Momentum with Reinforced Market Leadership
According to the announcement, the company achieved significant year-on-year revenue growth in its social networking business in 2025, primarily driven by the continued expansion of diversified social products supported by AI technology.
During the year, the company's social networking business achieved structural growth across global markets, with synergies among its "bush-like" portfolio of social apps. Products such as TopTop, a game-oriented social networking platform, maintained explosive growth, acting as key engines of expansion. Meanwhile, other core social apps continued to deliver stable revenue and cash flow contributions.
Particularly in the MENA region, Newborn Town has built significant competitive advantages and a robust product ecosystem. In Q4 2025, TopTop, supported by localized operations and a growing UGC ecosystem, further strengthened its market position and emerged as a nationally popular app in high-value markets such as Saudi Arabia.
The company's diverse-audience social networking business also sustained solid development in overseas markets. Through deepening community engagement, iterating social features, and launching brand campaigns, HeeSay has further solidified its leading position in Southeast Asia, boosting its brand influence.
As the social business continued to accelerate, Newborn Town's overall market competitiveness also strengthened. In December 2025, the company ranked 4th on Diandian's "Top Chinese non-gaming publishers by overseas revenue"list, up one place from the previous ranking, reflecting solid growth momentum.
The company's consistently improving localization capabilities remain a key driver of its competitive moat. A research report by CLSA in 2025 highlighted Newborn Town's distinctive competitive edge, enabled by deeper user insights, refined service experience, and diversified monetization models. With solid localization execution, Newborn Town has also demonstrated strong competitiveness in product innovation, user acquisition, and content operations.
Innovative Business Delivers Strong Growth as Quality Games Enter a Phase of Long-Term Operations
In 2025, Newborn Town's innovative business emerged as a strong growth engine. The growth was driven by sustained expansion in traffic monetization, social e-commerce business, revenue contributions from the short drama segment and its self-developed quality games.
Since Q4 2024, the quality games segment has entered its profit-harvesting phase. Flagship titles have now transitioned into long-term operations, delivering a meaningful increase in ARPU during the year. Building on the game team's growing expertise in the merge-game genre and the deeper integration of AI technologies, Newborn Town significantly shortened development cycles in 2025, while new game titles advanced steadily as planned.
Over the past year, Newborn Town's social e-commerce business delivered steady growth, while Heer Health further consolidated its leading position in the HIV prevention and sexual health services segment.
In 2025, Heer Health partnered with insurance companies and pharmaceutical firms to launch China's first critical illness insurance product specifically designed for people living with HIV, offering an innovative solution to long-standing challenges in insurance access for this group.
Meanwhile, the company's short-drama business has also begun to demonstrate early positive results.
AI Integration Accelerates Innovation-Driven Momentum
In 2025, Newborn Town continued to deepen its AI strategy, integrating AI into core business operations while launching a range of "AI + Social Entertainment" product innovations.
In terms of product innovation, the company launched Aippy, an AI-powered creative content community that lowers the barrier to creation for users without coding experience. By integrating advanced AIGC technologies, Aippy enables users to easily create mini-games and other interactive content. Since it launch, the mobile version has received encouraging user feedback, achieving an average rating of 4.9 on both the Apple App Store and major Android app stores.
AI technologies have now been embedded across all key operations, with the company's self-developed multimodal algorithm model, Boomiix, continuing to undergo iterative upgrades. By further deploying AI in core scenarios - from social recommendations, intelligent operations, advertising, risk management and content safety, and creative asset design, Newborn Town has consistently optimized user experience and operational efficiency.
In 2025, Newborn Town introduced Siyu, an AI-powered intelligent data platform enabling operations teams to efficiently query data, perform analytics and generate reports via natural-language interactions. The platform was subsequently selected as a flagship case by Amazon Web Services.
In September 2025, the company entered a strategic partnership with Tencent Cloud to jointly explore opportunities in "AI + Global Social Entertainment," leveraging both parties' technical strengths and market reach.
In June 2025, Newborn Town established its global headquarters in Hong Kong, marking a new milestone in its globalization strategy. Between November and December 2025, Newborn Town executed a series of share repurchases on the open market, with an aggregate amount exceeding HKD 80 million, demonstrating management's strong confidence in the company's long-term value and growth prospects. Moving forward, the company will continue to deepen its global business footprint and remain committed to creating positive emotional value for users.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Newborn Town Inc. Expects 2025 Revenue of RMB 6.76-7.00 Billion, Up Over 32% Year on Year
